← Leaderboards
Federico Cividini
Cardiac Rsk3 Inhibitors, Llc
$10,485,488
Attributed
$10,485,488
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.2M · FY2019–24$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,485,488 · 3
By mechanism
R44$10,485,488 · 3
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Gene Transduction Agent”
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Crystal Mackall · Children'S Hosp Of Philadelphia$13,090,386
- James Dale Berry · Brigham And Women'S Hospital$9,673,541
- Elizabeth Fox · St. Jude Children'S Research Hospital$8,840,232
- Tina Garyantes · Linnaeus Therapeutics, Llc$6,999,960
- Anna Koroleva · Medical Science & Computing, Llc$6,133,050
Research focus
Gene Transduction AgentHeartClinical TrialsFamily SuidaeFirst-In-HumanFibrosisCatheterizationClinically RelevantDependovirusDiagnosisEchocardiographyDoseBiologicalAnimalsA Kinase Anchoring ProteinCardiovascular DiseasesAttenuatedCellular PathologyCardiacAmericanCardiac MyocytesBindingAnimal ModelHeart Failure
Grant awards (8)
RSK3 Anchoring Disruptor Therapy for Heart Failure$1,982,787
R44 · FY2024 · HL · contact PI
RSK3 Anchoring Disruptor Therapy for Heart Failure$1,978,293
R44 · FY2023 · HL · contact PI
PP2A Anchoring Disruptor Therapy in Heart Failure$1,219,206
R44 · FY2023 · HL · contact PI
PP2A Anchoring Disruptor Therapy in Heart Failure$1,888,812
R44 · FY2022 · HL · contact PI
ShRNA-Based Targeting of mAKAPò in Heart Failure$885,032
R44 · FY2022 · HL · contact PI
ShRNA-Based Targeting of mAKAPò in Heart Failure$1,761,984
R44 · FY2021 · HL · contact PI
PP2A Anchoring Disruptor Therapy in Heart Failure$436,929
R44 · FY2021 · HL · contact PI
ShRNA-Based Targeting of mAKAPò in Heart Failure$332,445
R44 · FY2019 · HL · contact PI